Report from Industry Scientific Advisory Board

PPMI Annual Investigators Meeting
May 2-3, 2012

Thomas Comery
Industry Scientific Advisory Board (ISAB) Membership

- Abbott
  Michelle Collins
  Katherine Widnell

- Avid Radiopharmaceuticals
  Mark Mintun

- biogen idec
  Bernard Ravina, Chair-elect

- Covance
  Peggy Taylor

- elan
  Ted Yednock

- Genentech
  Marcel van der Brug

- GlaxoSmithKline
  Alastair Reith

- GE Healthcare
  Igor Grachev

- MERCK
  Johan Luthman
  David Michelson

- Pfizer
  Thomas Comery, Chair

- Roche
  Susanne Ostrowitzki
  Paulo Fontoura
Industry Scientific Advisory Board Role

- Stakeholder role of the ISAB
  - Support Steering Committee
  - Input in Taskforces/Working groups
  - Participate in Annual Meeting and bi-monthly t-cons
  - Support efforts to identify additional partners
  - Suggest Ancillary Studies
Ancillary Studies Under Consideration by the ISAB

1. Develop a standard data compilation for use by ISAB members

2. Development of a quantitative Parkinson’s disease progression model allowing:
   - simulation of potential trial designs (patient selection, trial size, duration)
   - improved understanding of the effect of drop-outs and placebo response
   - incorporation of biomarker-outcome relationships (neuropsychological, neuroimaging and biofluids)
Ancillary Studies Under Consideration by the ISAB

3. Addition of ASL-fMRI and spatial covariance analysis into PPMI
   - Analysis of brain metabolic activity has identified networks associated with motor impairment, cognitive deficits and tremor in PD
   - PPMI provides an opportunity to evaluate the robustness of these findings in a multi-center progression trial and correlate the findings with extensive motor and non-motor assessments

4. Characterization of $\alpha$-synuclein variants in CSF, plasma and serum as candidate biomarkers for Parkinson’s disease
   - Establish a profile of $\alpha$-synuclein variants in biofluids of older healthy volunteers and patients with Parkinson’s disease

Tang et al., 2010
Ancillary Studies Under Consideration by the ISAB

5. Support the expansion of PPMI to include a cohort at risk for developing PD
   - Addition of an at risk population is key as designs and patient identification strategies for potential disease modifying therapies are being developed
   - Establish pre-motor biomarker signature

Natural History of Parkinson’s Disease
ISAB Next Steps

• Continue to support the PPMI goals and objectives through ISAB bi-monthly t-cons and participation in working groups

• Formulate and communicate ISAB member’s needs as they arise

• Evaluate needs and gaps, recommend new ancillary studies to accelerate drug development in PD, biomarkers acceptance by regulators and develop new indications for approved products

• Support addition of new ISAB members to PPMI